Literature DB >> 9715808

Effects of antidepressant drugs on rats bred for low activity in the swim test.

C H West1, J M Weiss.   

Abstract

To determine responsivity to antidepressant medication of Sprague-Dawley rats bred for low activity in the swim test [Swim Low-Active (SwLo) rats], these animals were given different antidepressant drugs via subcutaneously implanted minipumps for 1, 12, or 26 days, and then were tested for activity in the swim test and 2 days later in the open field. Antidepressant drugs given were amitriptyline, imipramine, desipramine (tricyclics), phenelzine (monoamine oxidase inhibitor (MAOI)], fluoxetine [selective serotonin reuptake inhibitor (SSRI)], venlafaxine, and bupropion (atypical). To assess specificity of response, the nonantidepressant drugs amphetamine, caffeine, and haloperidol were also tested. For comparison, several drugs were also tested in rats bred for high activity in the swim test [Swim High-Active (SwHi) rats]. When administered for 14 and/or 28 days (but not for 1 day), imipramine, desipramine, venlafaxine, phenelzine, and bupropion significantly increased struggling behavior of SwLo rats in swim test. No nonantidepressant drug significantly elevated struggling activity. Long-term administration of phenelzine and bupropion also significantly decreased floating behavior in the swim test, although amphetamine also had this effect at all times of administration. No significant effects of antidepressants were seen in SwHi rats. Amitriptyline and fluoxetine were ineffective in altering either struggling or floating in SwLo rats; however, a high dose of an SSRI (sertraline) did reduce floating, but this type of effect is probably not indicative of antidepressant action. Behavior in the open field was not consistently affected by any drug type. It is concluded that, based on pharmacological response profile in the swim test, SwLo rats represent depression that is responsive to potent norepinephrine reuptake-blocking antidepressants and also MAOIs; atypical depression may fit this profile.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715808     DOI: 10.1016/s0091-3057(98)00076-8

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  20 in total

1.  A prescription to resist proscriptions for murine models of depression.

Authors:  I Lucki
Journal:  Psychopharmacology (Berl)       Date:  2001-01       Impact factor: 4.530

Review 2.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  Paroxetine-induced increase in activity of locus coeruleus neurons in adolescent rats: implication of a countertherapeutic effect of an antidepressant.

Authors:  Charles Hutchison Keesor West; James Carl Ritchie; Jay Michael Weiss
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

4.  Seizure susceptibility and epileptogenesis in a rat model of epilepsy and depression co-morbidity.

Authors:  S Alisha Epps; Kroshona D Tabb; Sharon J Lin; Alexa B Kahn; Martin A Javors; Katherine A Boss-Williams; Jay M Weiss; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

5.  Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants.

Authors:  Robert C Drugan; Heather Macomber; Timothy A Warner
Journal:  Psychopharmacology (Berl)       Date:  2010-07-10       Impact factor: 4.530

6.  A selective test for antidepressant treatments using rats bred for stress-induced reduction of motor activity in the swim test.

Authors:  Charles Hutchison Keesor West; Jay Michael Weiss
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Rats bred for susceptibility to depression-like phenotypes have higher kainic acid-induced seizure mortality than their depression-resistant counterparts.

Authors:  Kroshona Tabb; Katherine A Boss-Williams; Jay M Weiss; David Weinshenker
Journal:  Epilepsy Res       Date:  2007-04-02       Impact factor: 3.045

8.  Bupropion attenuates nicotine abstinence syndrome in the rat.

Authors:  David H Malin; J Ronald Lake; Tanya D Smith; Habil N Khambati; Rhonda L Meyers-Paal; Ana L Montellano; Ryan E Jennings; Daniel S Erwin; Stacey E Presley; Barbara A Perales
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

9.  A novel approach for predicting antidepressant-induced sexual dysfunction in rats.

Authors:  Stacey J Sukoff Rizzo; Lee E Schechter; Sharon Rosenzweig-Lipson
Journal:  Psychopharmacology (Berl)       Date:  2007-09-16       Impact factor: 4.530

10.  Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons.

Authors:  Charles H K West; James C Ritchie; Katherine A Boss-Williams; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2008-10-27       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.